Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid epidemic.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades](

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit patients’ ability to access it.

On Jan. 30, the U.S. Food and Drug Administration (FDA) approved a new drug called suzetrigine to treat moderate-to-severe pain. The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals,

The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx (suzetrigine), for adults with moderate to severe acute pain. Developed by Vertex Pharmaceuticals,